Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Gel Clear all
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

NCT02355158
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes
Interventions
clonidine hydrochloride topical gel, 0.1%
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

NCT00444626
View directory record Official record
Conditions
Facial Wrinkles at the Nasolabial Folds
Interventions
Dermal Gel Extra (DGE), Restylane, EMLA Cream
Device · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • La Jolla, California • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

NCT02651220
View directory record Official record
Conditions
Acne
Interventions
Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 17, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Therapeutic Hypothermia in Patients With ARDS

NCT04545424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Starting a Testosterone and Exercise Program After Hip Injury

NCT02938923
View directory record Official record
Conditions
Hip Fracture, Frailty, Sarcopenia
Interventions
Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 17, 2026, 5:22 AM EDT
Not yet recruiting Phase 4 Interventional

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

NCT07636161
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions
Eroxon®, tadalafil
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Azelaic Acid on Demodex Counts in Rosacea

NCT03035955
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308033
View directory record Official record
Conditions
Vaginal Infection
Interventions
Metronidazole, Gel vehicle
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 17, 2026, 5:22 AM EDT
Recruiting Not applicable Interventional

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

NCT07630155
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Analgesic Agent, Electronic Health Record Review, Lidocaine Topical, Medical Device Usage and Evaluation, Survey Administration, Ureteroscopy
Drug · Other · Device + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Treating Word Finding Difficulties in Traumatic Brain Injury With HD-tDCS

NCT06840808
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Change, Word Finding Difficulty, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

A Study of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes

NCT01319149
View directory record Official record
Conditions
Wounds
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 17, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the Next Science SurgX Antimicrobial Wound Gel Impact on Surgical Site Complications

NCT05517278
View directory record Official record
Conditions
Total Hip Arthroplasty, Total Knee Arthroplasty
Interventions
SurgX Antimicrobial Wound Gel, Standard of Care
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

NCT01129284
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin

NCT00652314
View directory record Official record
Conditions
Operation Site Bleed
Interventions
Thrombi-Gel
Device
Lead sponsor
Vascular Solutions LLC
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Springfield, Illinois • Burlington, Massachusetts • Flint, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy

NCT03329131
View directory record Official record
Conditions
Peripheral Neuropathies
Interventions
Cryotherapy
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 17, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

NCT04469075
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
Interventions
Clindamycin Phosphate, Triamcinolone Acetonide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Evanston, Illinois • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

NCT04456296
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Interventions
Aveed Injectable Product, Fortesta, Testim
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 17, 2026, 5:22 AM EDT
Recruiting Not applicable Interventional

Non-invasive VNS for Parkinson's Gait

NCT06562569
View directory record Official record
Conditions
Parkinson's Disease
Interventions
non-invasive cervical vagal nerve stimulation ncVNS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 5:22 AM EDT